Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition
| dc.contributor.author | Bentanachs Raset, Roger | |
| dc.contributor.author | Miró Martí, Ma. Lluïsa | |
| dc.contributor.author | Ramírez-Carrasco, Patricia | |
| dc.contributor.author | Sánchez, Rosa María | |
| dc.contributor.author | Bernabeu Lorenzo, Manuel | |
| dc.contributor.author | Amat, Concepció | |
| dc.contributor.author | Alegret i Jordà, Marta | |
| dc.contributor.author | Pérez Bosque, Anna | |
| dc.contributor.author | Roglans i Ribas, Núria | |
| dc.contributor.author | Laguna Egea, Juan Carlos | |
| dc.date.accessioned | 2026-01-16T08:36:03Z | |
| dc.date.available | 2026-01-16T08:36:03Z | |
| dc.date.issued | 2025-04-14 | |
| dc.date.updated | 2026-01-16T08:36:03Z | |
| dc.description.abstract | In the present work, we analyse stored liver, adipose tissue (perigonadal</p><p>and brown), serum and faecal samples from our previous study and present new</p><p>biochemical, faecal metabolomic and microbiome data.</p><p>We show that oral administration of mirabegron</p><p>significantly increases the expression of uncoupling protein 1 in brown</p><p>adipose tissue and β3-Adrenergic receptor protein in perigonadal white</p><p>adipose and liver tissues. Furthermore, mirabegron treatment changes the</p><p>relative abundance of several genus and families of rat faecal microbiota,</p><p>albeit without restoring the global biodiversity and evenness indexes observed</p><p>in control rats, as well as faecal bile acids composition. These changes are</p><p>probably due to a direct effect of mirabegron on the gut microbiome, rather</p><p>than being mediated by changes in bile acid induced by drug treatment. | |
| dc.format.extent | 13 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 759620 | |
| dc.identifier.issn | 1663-9812 | |
| dc.identifier.uri | https://hdl.handle.net/2445/225599 | |
| dc.language.iso | eng | |
| dc.publisher | Frontiers Media | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fphar.2025.1547749 | |
| dc.relation.ispartof | Frontiers in Pharmacology, 2025 | |
| dc.relation.uri | https://doi.org/10.3389/fphar.2025.1547749 | |
| dc.rights | cc-by (c) Bentanachs, R. et al., 2025 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject.classification | Metabolisme | |
| dc.subject.classification | Malalties del fetge | |
| dc.subject.classification | Teixit adipós | |
| dc.subject.other | Metabolism | |
| dc.subject.other | Liver diseases | |
| dc.subject.other | Adipose tissues | |
| dc.title | Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1